secwatch.observer — SEC 8-K summary
======================================

Issuer:     SQZ Biotechnologies Co (—)
CIK:        0001604477
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-051187
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 2.06, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

SQZ Biotech cuts ~80% of workforce, estimates $22M non-cash impairment
----------------------------------------------------------------------

- Board approved ~80% workforce reduction on Sep 29, 2023 to cut costs while pursuing strategic alternatives.
- Expected $1.5M in severance charges (mostly Q3 2023); ~$100K cash expenditure.
- Non-cash impairment of ~$22M related to facility lease right-of-use asset and equipment.
- Interim CEO, CAO, CMO, and GC to have reduced salaries and terminate Nov 15, 2023; may become consultants.
- Company plans to continue treating currently enrolled patients in eAPC and AAC programs for HPV16+ tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/sqzb-20230929.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer